ArticleGhana medical journal2021
Epidemiological features of brucellosis and factors affecting its treatment failure and relapse in Qom Province, Iran.
Article in Ghana medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Frequency of Human Brucellosis Complications in West Asia: A Systematic Review and Meta-Analysis.MicrobiologyOpen · 2026Pooled it
- Determinants of relapse and delayed convalescence in patients with Brucellosis: a one-year prospective follow-up.Irish journal of medical science · 2026Article
- Pediatric brucellosis: predictors of hospitalization, complications, and relapse in a nationwide multicenter cohort.European journal of pediatrics · 2026Article
- Brucellosis relapse: Rate, patient characteristics, and clinical outcomes in an endemic region.PLoS neglected tropical diseases · 2025Article
- Incidence and warning signs for complications of human brucellosis: a multi-center observational study from China.Infectious diseases of poverty · 2024Observational
- What Could Lead to the Production of Anti-Rheumatoid Antibodies in Patients with Brucellosis Spondylodiscitis: Possible Causes.Medical journal of the Islamic Republic of Iran · 2024Article
- Massive cardiac vegetation and cardiomyopathy in a 23-year-old rancher with brucellosis.Clinical case reports · 2023Article
- Article
- Comparative Study on the Efficacy of Two Perioperative Chemotherapy Regimens for Lumbar Brucellosis.Drug design, development and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brucellosis is one of the major health problems in many areas of the world, especially in the Mediterranean and the Middle East regions. Objective: To determine the epidemiological characteristics, clinical signs, and risk factors of relapse rate in patients with brucellosis, Qom Province, Iran. Methods: A descriptive-analytic study was conducted on 410 confirmed brucellosis cases in Qom Province, central Iran, from 2015 to 2019, based on epidemiological checklists and according to the Iran Ministry of Health and Medical Education (MOHME). Univariate and multiple logistic regression analyses were conducted using Stata software version 14. Results: The relapse rate of brucellosis was 6.6% until nine months after starting the treatment, and all recurrent cases were infected by Conclusion: The delayed initiation of treatment was a significant factor influencing the relapse of brucellosis; therefore, it is necessary to provide enough diagnostic and laboratory facilities, and people need to be educated about the signs and symptoms of the disease. Funding: Funding for this research was provided by the Research and Technology Center of Qom University of Medical Sciences, Qom, Iran.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.